Skip to menu Skip to content Skip to footer

2022

Conference Publication

Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo

Wright, Q., Sinha, D., Gonzalez-Cruz, J., Frazer, I. and Leggatt, G. (2022). Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo. ESMO Immuno-Oncology Congress 2022, Geneva, Switzerland, 7-9 December 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.iotech.2022.100289

Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo

2021

Conference Publication

Preclinical assessment of off-the-shelf allogeneic T-cell therapy for the treatment of multiple Epstein-Barr virus-associated malignancies

Sinha, D. and Khanna, R. (2021). Preclinical assessment of off-the-shelf allogeneic T-cell therapy for the treatment of multiple Epstein-Barr virus-associated malignancies. ISCT2021, Virtual, 26-28 May 2021. Oxford, United Kingdom: Elsevier. doi: 10.1016/s1465324921004151

Preclinical assessment of off-the-shelf allogeneic T-cell therapy for the treatment of multiple Epstein-Barr virus-associated malignancies

2019

Conference Publication

Strategic inhibition of CEP55 in aggressive breast cancer leads to mitotic catastrophe

Sinha, D. (2019). Strategic inhibition of CEP55 in aggressive breast cancer leads to mitotic catastrophe. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press.

Strategic inhibition of CEP55 in aggressive breast cancer leads to mitotic catastrophe

2019

Conference Publication

Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer

Raninga, P., Lee, A., Sinha, D., Shin, Y-Y., Mittal, D., Kalimutho, M. and Khanna, K. K. (2019). Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press.

Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer

2018

Conference Publication

CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo

Sinha, D., Kalimutho, M., Bain, A.L. and Khanna, K.K. (2018). CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo. 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherlands, 30 June – 3 July 2018. London, United Kingdom: Elsevier. doi: 10.1136/esmoopen-2018-eacr25.730

CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo

2017

Conference Publication

Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer

Sinha, D., Kalimutho, M., Lopez, A. J. and Khanna, K. K. (2017). Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: OXFORD UNIV.

Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer

2017

Conference Publication

Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer

Raninga, P., Kalimutho, M., Sinha, D., Bain, A., Tonissen, K. and Khanna, K. K. (2017). Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer. 42nd European Society for Medical Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: Oxford University Press.

Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer

2017

Conference Publication

Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression

Sinha, Debottam, Kalimutho, Murugan, Lopez, J. Alejandro and Khanna, Kum Kum (2017). Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC , United States, 1-5 April 2017. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2017-1144

Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression

2012

Conference Publication

Studies on the Dielectric properties of Natural Urinary Stones

Sinha, Debottam, Anwar, K., Kumari, K., Jaishwal, S., Madeshwaran, S., Keshari, S., Babu, D. Rajan, Vidya, R. and Nambiraj, Arunai N. (2012). Studies on the Dielectric properties of Natural Urinary Stones. International Conference on Recent Trends in Advanced Materials (ICRAM 2012), Vellore, India, 20-22 February 2012. Baech, Switzerland: Scientific.Net. doi: 10.4028/www.scientific.net/amr.584.484

Studies on the Dielectric properties of Natural Urinary Stones